WR Wealth Planners LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 10.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,765 shares of the medical instruments supplier’s stock after selling 312 shares during the period. WR Wealth Planners LLC’s holdings in Becton, Dickinson and Company were worth $627,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of Jackson Hole Trust purchased a new stake in Becton, Dickinson and Company in the 4th quarter valued at about $25,000. Sierra Ocean LLC bought a new position in shares of Becton, Dickinson and Company during the 4th quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $33,000. Tompkins Financial Corp grew its position in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Finally, Kennebec Savings Bank bought a new position in shares of Becton, Dickinson and Company during the 3rd quarter valued at approximately $46,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.
Becton, Dickinson and Company Stock Up 0.6 %
BDX opened at $225.57 on Friday. The company has a 50 day moving average of $233.08 and a 200 day moving average of $233.05. The company has a market cap of $64.77 billion, a PE ratio of 37.47, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $251.99. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69.
Becton, Dickinson and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be issued a $1.04 dividend. This represents a $4.16 annualized dividend and a yield of 1.84%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.
Becton, Dickinson and Company announced that its board has authorized a stock buyback plan on Tuesday, January 28th that authorizes the company to buyback 10,000,000 outstanding shares. This buyback authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.
Wall Street Analysts Forecast Growth
BDX has been the subject of a number of research reports. Piper Sandler increased their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research report on Tuesday, January 28th. Barclays increased their target price on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Finally, StockNews.com downgraded shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $278.29.
Get Our Latest Report on Becton, Dickinson and Company
Insider Buying and Selling at Becton, Dickinson and Company
In other Becton, Dickinson and Company news, EVP Roland Goette sold 4,483 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the transaction, the executive vice president now directly owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This trade represents a 15.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael David Garrison sold 2,838 shares of the firm’s stock in a transaction on Thursday, December 19th. The shares were sold at an average price of $223.33, for a total transaction of $633,810.54. Following the completion of the transaction, the executive vice president now directly owns 6,141 shares of the company’s stock, valued at approximately $1,371,469.53. The trade was a 31.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,544 shares of company stock valued at $2,370,309 in the last three months. Company insiders own 0.36% of the company’s stock.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.
Featured Articles
- Five stocks we like better than Becton, Dickinson and Company
- When to Sell a Stock for Profit or Loss
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- The 3 Best Retail Stocks to Shop for in August
- 5 Best Gold ETFs for March to Curb Recession Fears
- What is the S&P/TSX Index?
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.